Table 2.
Resistances among ESBL-producing E. coli isolates.
| Antibiotic | Resistance | Susceptibility | Intermediate |
|---|---|---|---|
| Beta-lactam family | |||
| Amoxicillin (AMX) | 252 (100%) | 1 (0%) | 0 |
| Amoxicillin/clavulanic acid (AMC) | 171 (67%) | 83 (33%) | 0 |
| Piperacillin/tazobactam (TZP) | 97 (40%) | 115 (47%) | 32 (13%) |
| Ticarcillin (TIC) | 176 (98%) | 4 (2%) | 0 |
| Cefoxitin (FOX) | 25 (10%) | 212 (88%) | 3 (2%) |
| Ceftazidime (CAZ) | 225 (90%) | 18 (7%) | 8 (3%) |
| Cefotaxime (CTX) | 208 (91%) | 8 (3%) | 13 (6%) |
| Cefixime (CFM) | 231 (96%) | 7 (3%) | 2 (1%) |
| Imipenem (IPM) | 7 (3%) | 218 (96%) | 2 (1%) |
| Ertapenem (ETP) | 2 (1%) | 199 (98%) | 2 (1%) |
| Others antibiotic family | |||
| Gentamicin (GM) | 102 (41%) | 140 (56%) | 7 (3%) |
| Tobramycin (TM) | 183 (73%) | 57 (23%) | 10 (4%) |
| Amikacin (AN) | 46 (19%) | 162 (66%) | 37 (15%) |
| Norfloxacin (NX) | 231 (93%) | 14 (6%) | 4 (1%) |
| Trimethoprim/sulfamethoxazole (SXT) | 184 (80%) | 45 (20%) | 0 |
| Fosfomycin (FOS) | 5 (2%) | 235 (98%) | 0 |
| Colistin (CT/CL) | 1 (0%) | 223 (100%) | 0 |